Partial List of Products Bearing the Same Neutral Code associated with QP Pharmachem
Photos of products containing the same neutral code as QP Pharmachem.
Photos of products containing the same neutral code as QP Pharmachem.
The examination of IndiaMART’s verification processes reveals significant issues with transparency and safety in the pharmaceutical sector. Notably, QP Pharmachem, a manufacturer of anabolic steroids and previously flagged for producing contaminated medications, remains a verified supplier. Companies like Matrix Biolabs and Evolve Biolabs claim WHO-GMP and ISO certifications without providing verifiable evidence. The neutral code system, crucial for tracking manufacturing origins, links these companies to QP Pharmachem, raising concerns about product quality and regulatory compliance. This article highlights the importance of thorough verification and regulatory oversight to protect consumers and maintain the integrity of the pharmaceutical industry.
Prime Minister Narendra Modi’s directive for Indian pharmaceutical plants to achieve WHO GMP certification by the end of 2023 faces significant resistance from some manufacturers. The Pundrug Research Foundation, led by several Punjab-based pharmaceutical companies, argues that the financial and logistical burdens of upgrading to meet these standards are too high, particularly for smaller firms. Despite these challenges, the Indian government emphasizes that such upgrades are essential for ensuring the safety, efficacy, and global competitiveness of Indian pharmaceuticals. The debate underscores the critical need for balancing regulatory compliance with economic realities to maintain India’s position as a leading pharmaceutical producer.
Prime Minister Narendra Modi has set a transformative goal for India’s pharmaceutical industry: by the end of 2023, all pharmaceutical manufacturing plants must adhere to WHO Good Manufacturing Practices (GMP) certification, also known as Schedule M. This directive aims to elevate the quality of India’s pharmaceutical products to meet international standards, ensuring that all medications produced in the country are safe, effective, and of high quality. This ambitious mandate faces significant challenges, including the need for infrastructure upgrades, comprehensive training for personnel, and continuous regulatory compliance. However, the long-term benefits of improved global competitiveness, enhanced industry credibility, and better patient safety make it a crucial move for the Indian pharmaceutical sector.